SIGA Technologies logo
SIGA Technologies SIGA
$ 3.45 6.15%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

SIGA Technologies Income Statement 2025-2008 | SIGA

Brief overview of financial results at SIGA Technologies

The conclusions below are based on five years of reported results. Revenue reported by SIGA Technologies was $125 million at the beginning of the period and $94.6 million at the end. Overall revenue changed by −24.3%, equal to an annualized rate of about −5.4%. The decline points to a contraction in the scale of the business.

The five-year change in gross profit reached −41.1%: from $110 million to $64.9 million. The cost base moved against the top-line trend and weighed on the gross result. At the margin level, the figure shifted from 88.2% to 68.6%. The contraction points to pressure from direct costs or weaker pricing power.

EBITDA was 85 million dollars at the beginning and 24.3 million dollars at the end of the period (−71.5%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 68% at the start and 25.7% at the end. The business retained less EBITDA from each unit of revenue.

Net profit was $56.3 million at the start and $23.3 million at the end. Profit pressure may reflect higher operating, financing, or tax costs.

Over the period, capitalization shifted from 501 million dollars to 404 million dollars (−19.3%). Market expectations deteriorated over the period.

Financial takeaway

The indicators point to a weaker financial profile. The main areas of concern are a softer top-line trend, declining net profitability and pressure from direct costs. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement SIGA Technologies

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

404 M 403 M 380 M 489 M 452 M 501 M 422 M 528 M 386 M 173 M 25.3 M 75.3 M 175 M 151 M 172 M 302 M 296 M -

Shares

71.5 M 71.3 M 71.4 M 72.9 M 75.3 M 79.3 M 81 M 79.9 M 78.9 M 57.2 M 53.8 M 53.4 M 52.4 M 51.6 M 50.9 M 45.2 M 37.5 M -

Historical Prices

5.65 5.65 5.32 6.71 6 6.32 5 6.78 6.6 3.29 0.68 2.27 3.21 4.28 2.85 6.69 7.89 3.01

Net Income

23.3 M 59.2 M 68.1 M 33.9 M 69.5 M 56.3 M -7.24 M 422 M -36.2 M -39.7 M -39.5 M -265 M -17.2 M -14.5 M 13.6 M -50.3 M -19.4 M -

Revenue

94.6 M 139 M 140 M 111 M 134 M 125 M 26.7 M 477 M 12.3 M 15 M 8.18 M 3.14 M 5.52 M 8.97 M 12.7 M - - -

Cost of Revenue

29.7 M 31.3 M 17.8 M 10.4 M 16.6 M 14.8 M 1.78 M 95.3 M - - - - - - - - - -

Gross Profit

- - - - - - 11.7 M 369 M -4.41 M -4.72 M -4.95 M -7.69 M -8.34 M -9.24 M 12.7 M - - -

Operating Income

23.7 M 70 M 83.6 M 42.7 M 89.1 M 84.5 M -2.32 M 355 M -18.8 M -31 M -31 M -210 M -23.5 M -22.5 M -31.4 M -12.7 M -11.9 M -

Interest Expense

- - - - - 3.02 M 15.8 M 15.5 M 14.8 M 2.4 M 267 K 456 K 1.21 M 173 K - - - -

EBITDA

24.3 M 70.5 M 84.2 M 43.2 M 89.6 M 85 M -1.8 M 355 M -17.5 M -19.2 M -16.3 M -20.9 M -22.5 M -22.1 M -30.8 M -12.1 M -11.4 M -

Operating Expenses

- - - - - - 14 M 13.7 M 13.2 M 14.6 M 11.6 M 13.5 M 14.7 M 13.3 M 44.1 M 31.9 M 25.7 M -

General and Administrative Expenses

21.2 M 25.1 M 22 M 35.1 M 18 M 14.7 M 13.3 M 12.9 M 12.3 M 13.7 M 10.6 M 12.5 M 13.2 M 11.4 M 25.7 M 8.13 M 7.53 M -

All numbers in USD currency

Quarterly Income Statement SIGA Technologies

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

71.8 M 71.6 M 71.6 M 71.5 M 71.4 M 71.4 M 71.4 M 71.2 M 71.1 M 71.1 M 71.1 M 71.1 M 72.2 M 72.7 M 73 M 72.7 M 73.1 M 73.5 M 74.8 M 75.8 M 76.8 M 77.2 M 78.1 M 80.3 M 81.2 M 81.3 M 81.1 M 81 M 80.9 M 80.8 M 80 M 79.1 M 79 M 78.9 M 78.9 M 78.8 M 78.8 M 79 M 54.3 M 54.2 M 54.1 M 78.7 M 53.9 M 53.6 M 53.5 M 53.5 M 53.5 M 53.4 M 53.3 M 53.1 M 52.5 M 52.2 M 51.7 M 51.6 M 51.6 M 51.6 M 51.6 M 51.6 M 50.8 M 50.9 M 50 M

Net Income

12.5 M -3.45 M -6.37 M 35.5 M -408 K - 1.34 M 1.83 M 10.3 M - -393 K -2.88 M -918 K - 33 M 2.04 M -361 K - -3.11 M 169 K -812 K - 24.2 M 20.9 M -8.9 M -4.5 M -1.21 M -3.16 M 1.63 M 52.4 M 388 M -7.05 M -11.6 M -10.3 M -9.82 M -7.5 M -8.62 M -10.4 M -9.24 M -9.57 M -10.4 M -20.1 M -5.63 M -6.57 M -7.15 M -19.1 M -240 M -2.95 M -3.38 M -4.34 M -4.9 M -3.06 M -4.88 M -2.62 M -3.06 M -3.77 M -4.62 M -5.06 M 8.33 M 27.3 M -1.51 M

Revenue

41 M 6.24 M 2.62 M 81.1 M 7.04 M - 10 M 21.8 M 25.4 M - 9.24 M 5.88 M 8.32 M - 72.2 M 16.7 M 10.5 M - 4.85 M 8.65 M 4.81 M - 44.3 M 40.3 M 2.62 M 4.26 M 8.11 M 3.91 M 10.5 M 1.57 M 471 M 2.66 M 1.75 M 1.41 M 1.39 M 4.26 M 5.2 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

17.6 M 2.94 M 1 M 25.6 M 158 K - 1.62 M 12.3 M 3.23 M - 897 K 974 K 1.15 M - 3.95 M 882 K 4.72 M - 83.3 K 996 K 251 K - 5.56 M 4.8 M 109 K 130 K 737 K - 915 K 103 K 95.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

13.9 M -5.32 M -10.2 M 45.7 M -2.26 M - 542 K 1.08 M 11.3 M - -1.31 M -4.64 M -2.11 M - 42.9 M 3.07 M -1.44 M - -2.94 M 1.1 K -1.99 M - 32.9 M 28.8 M -4 M -3.47 M 661 K -1.71 M 2.19 M -5.54 M 369 M -3.71 M -4.54 M -4.87 M -5.65 M -4.06 M -4.27 M -6.61 M -8.06 M -9.28 M -7.06 M -18 M -3.63 M -4.33 M -5.04 M -17.6 M -182 M -4.75 M -5.64 M -6.51 M -5.56 M -5.63 M -5.81 M -5.26 M -5.4 M -6.33 M -5.55 M -7.77 M -6.04 M -11.1 M -6.46 M

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - 3.02 M - 3.97 M 3.97 M 3.93 M - 3.92 M 3.84 M 3.75 M - 3.74 M 3.65 M 3.61 M - 94.8 K 10.2 K - - - 13.3 K 253 K - 105 K 124 K 141 K - 293 K 376 K 374 K - - - - - - - -

EBITDA

14.2 M -5.17 M - - -2.12 M - - - 11.4 M - - - -1.98 M - 43.3 M 3.07 M -1.31 M - -2.55 M 1.1 K -1.86 M - 33.3 M 29.1 M -3.86 M -3.47 M 791 K -1.58 M 2.33 M -5.54 M 369 M -3.71 M -4.51 M -4.87 M -5.62 M -4.02 M -4.23 M -6.61 M -8.02 M -9.24 M -7.01 M -18 M -3.58 M -4.26 M -4.96 M -17.6 M -182 M -4.66 M -5.55 M -6.51 M -5.45 M -5.53 M -5.71 M -5.26 M -5.09 M -6.12 M -5.45 M -7.77 M -5.58 M -10.8 M -6.3 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - 7.45 M 5.61 M 8.27 M - 102 M 6.37 M 6.28 M - 7.04 M 8.32 M 9.47 M - 12.7 M 11.2 M 8.33 M - 4.96 M 5.8 M 6.23 M - 183 M 5.4 M 6.19 M - 7.86 M 6.6 M 7.13 M - 7.69 M 9.03 M 7.01 M - 9.62 M 13.6 M 8.16 M

General and Administrative Expenses

5.15 M 4.67 M 4.79 M 5.49 M 5.68 M - 4.82 M 5.53 M 7.88 M - 6 M 4.43 M 4.24 M - 19.7 M 5.87 M 3.71 M - 4.47 M 5.22 M 4.06 M - 3.57 M 3.87 M 3.18 M 3.5 M 3.2 M 3.39 M 3.17 M 3.83 M 3.12 M 2.88 M 3.06 M 3.28 M 3.09 M 3.06 M 2.87 M 4.46 M 2.86 M 3.74 M 2.66 M 2.57 M 2.32 M 2.6 M 3.09 M 2.42 M 4.31 M 2.75 M 3.04 M 3.73 M 3.22 M 3.12 M 2.98 M 2.58 M 3.14 M 3.48 M 2.21 M 6.36 M 3.97 M 9.35 M 4.25 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company SIGA Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.0 1.83 % $ 1.48 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.88 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.26 0.06 % $ 11.6 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 98.52 0.24 % $ 23.8 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.99 0.84 % $ 1.25 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.98 0.3 % $ 247 M usaUSA
Codexis Codexis
CDXS
$ 1.32 1.09 % $ 115 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Cerus Corporation Cerus Corporation
CERS
$ 2.62 0.38 % $ 499 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.13 0.43 % $ 132 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.1 1.16 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.25 3.16 % $ 51.9 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.8 0.72 % $ 4.69 M usaUSA
AbbVie AbbVie
ABBV
$ 264.34 0.09 % $ 468 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.17 1.74 % $ 13.2 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.7 0.4 % $ 3.79 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.4 2.65 % $ 286 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.53 0.2 % $ 713 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 116.1 4.93 % $ 12.1 B usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.24 0.74 % $ 82.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.14 0.19 % $ 95.1 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Curis Curis
CRIS
$ 0.83 1.1 % $ 10.9 M usaUSA
CorMedix CorMedix
CRMD
$ 7.85 1.03 % $ 565 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 54.23 0.23 % $ 4.88 B schweizSchweiz
Champions Oncology Champions Oncology
CSBR
$ 4.9 0.1 % $ 67.8 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.62 8.21 % $ 918 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.41 1.45 % $ 2.98 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.67 2.38 % $ 13.4 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 64.66 0.17 % $ 7.77 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.78 4.73 % $ 8.72 M usaUSA
Adagene Adagene
ADAG
$ 2.93 2.86 % $ 173 M chinaChina
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.94 1.4 % $ 373 M usaUSA